Bavarian Nordic Marburg vaccine receives $18.9 million from U.S. government
The U.S. Department of Homeland Security Science and Technology Directorate and the U.S. National Institutes of health declared their support of Bavarian Nordic's recombinant Modified Vaccinia virus Ankara-based vaccines, according to Sacbee.com.
The NIH contract, valued at up to $17.9 million, is for the advanced development of an MVA-BN human vaccine against Marburg virus and the evaluation of new technologies to increase its efficacy. The remaining funding from DHS is to be used to develop an MVA-BN animal vaccine against foot-and-mouth disease.
"These new contracts demonstrate the versatility of our MVA-BN platform for infectious disease vaccines and cancer immunotherapeutics," Anders Hedegaard, the president and CEO of Bavarian Nordic A/S, said, Sacbee.com reports. "The MVA-BN platform has broad applicability, an excellent safety profile and established manufacturing capacity, making it one of the most attractive vaccine technologies to meet the U.S. government's preparedness needs, as well as demonstrating commercial value."
MVA-BN is an adaptable vaccine platform that Bavarian Nordic says is suitable for a variety of infectious diseases, including biological threats like smallpox. The new contracts build on previous funding offered by the Biomedical Advanced Research Project Authority and NIH's National Institute of Allergy and Infectious Diseases.